---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Place in treatment, anticipated use, and care setting. Topics: Guideline treatment sequence for resistant hypertension, Guideline treatment sequence and specialist referral: ICER summary of the 2025 guideline, Proposed indication: use with other antihypertensive drugs, Labeled place of the first aldosterone synthase inhibitor, and 6 further topics. 11 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

- Guideline sequence: The 2025 AHA/ACC guideline starts drug treatment of resistant hypertension with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic, then adds spironolactone (25 to 50 mg/day) as the fourth drug. Amiloride (10 to 20 mg) is the alternative when spironolactone or eplerenone is not tolerated, followed by beta-blockers, alpha blockers, central sympatholytic drugs, direct vasodilators, or aprocitentan. Renal denervation is reserved for adults with intolerable side effects to optimal drug regimens. ICER summarizes the guideline as recommending referral to a specialist for a known or suspected secondary cause or when blood pressure remains uncontrolled after more than 6 months of treatment.
- Anticipated use: Mineralys submitted the NDA for the treatment of hypertension in combination with other antihypertensive drugs, the same wording as the first part of the BAXFENDY (baxdrostat) indication, which adds adults not adequately controlled on other agents. Mineralys describes its target as third-line or later treatment, with resistant hypertension as the initial segment and a “beachhead at fourth line”. Manufacturers told ICER that they view aldosterone synthase inhibitors as appropriate for third- or fourth-line therapy regardless of whether a third first-line agent had been tried.
- ICER populations and clinical input: ICER assessed three populations: resistant hypertension not at goal; blood pressure above goal on two drugs with intolerance of a third first-line agent; and blood pressure above goal on two drugs without a trial of a third first-line agent. ICER consulted five clinical experts (two internists, two cardiologists, one nephrologist), who identified mineralocorticoid receptor antagonists such as spironolactone as the preferred option for people who remain uncontrolled despite regular medication use.
- Care setting: Lorundrostat is orally administered. Mineralys estimates about 60,000 physicians write half of the third-line or later prescriptions, with a 60/40 split between primary care and specialists, most of whom are cardiologists. The guideline assigns routine and complex hypertension care to primary care physicians and cardiologists, and complex care involving secondary causes or resistant hypertension to nephrologists, endocrinologists, and hypertension specialists.

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm); [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.2.2.2-2"></a>

### Guideline treatment sequence for resistant hypertension

> “Antihypertensive drug therapy should start with a combination of an ACEi or ARB, a CCB, and a diuretic.”
> “RCTs have shown that addition of spironolactone (25-50 mg/day) as the fourth drug reduced home and 24-hour SBP by 6.6 to 8.7 mm Hg when compared with placebo in patients with resistant hypertension and eGFR ≥45 mL/min/1.73 m2”
> “When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10-20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension.”
> “Other alternative fourth- and fifth-line drug therapies include BBs, alpha blockers, central sympatholytic drugs, and direct vasodilators.”
> “RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.2-3"></a>

### Guideline treatment sequence and specialist referral: ICER summary of the 2025 guideline

> “For resistant hypertension, which is defined as blood pressure above goal despite use of 3 antihypertensive medications with complementary mechanisms of action (including a diuretic) or blood pressure at goal on 4 or more antihypertensive medications, guideline recommendations include screening for secondary causes of hypertension, maximizing diuretic therapy, and adding spironolactone or eplerenone.”
> “If an additional agent is still needed, it is recommended to add agents with a different mechanism of action (e.g., beta-blocker, nondihydropyridine calcium channel blockers, vasodilators, dual endothelin-receptor antagonists).”
> “Finally, referral to a specialist is recommended for a known or suspected secondary cause(s) of hypertension, or if blood pressure remains uncontrolled after more than 6 months of treatment.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-4"></a>

### Proposed indication: use with other antihypertensive drugs

> “Based on the positive results from our pivotal program, we submitted an NDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs.”
> “Launch-HTN evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to participants’ existing, prescribed background treatment of two to five antihypertensive medications.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.2-5"></a>

### Labeled place of the first aldosterone synthase inhibitor

> “BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

<a id="topic-2.2.2.2-6"></a>

### Manufacturer positioning: third-line or later use

> “We believe the Launch-HTN and Advance-HTN trial results demonstrate the opportunity for lorundrostat in third-line or later treatment of patients with hypertension.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “As it relates to some of the dialogues that we have had with payers, we continue to feel bullish as it relates to access, particularly where we have targeted lorundrostat use. That is that third line or later. We think resistant is the natural opening space, and with experience, both from a physician standpoint and demand growing into the third-line usage.”
> “I can tell you, as Eric alluded to and I did in my prior comments, that based on the research we have done with payers right now, the value proposition of lorundrostat certainly resonates fourth line, with some payers even third line. I think it is going to be, as I noted, a beachhead at fourth line.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.2.2.2-7"></a>

### Manufacturer positioning reported by ICER

> “Manufacturers suggested that they viewed aldosterone synthase inhibitors as appropriate for either third- or fourth-line therapy for patients with high blood pressure who are not at goal, regardless of whether patients had trialed a third first-line agent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-8"></a>

### ICER assessment populations

> “We evaluated the net health benefits of baxdrostat and lorundrostat in three populations: (1) resistant hypertension not at goal; (2) blood pressure above goal while on two antihypertensive medications and did not tolerate a third first-line agent; and (3) blood pressure above goal while on two antihypertensive medications and who have not been treated with a third first-line agent.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-9"></a>

### Clinical expert views reported by ICER

> “We spoke with five clinical experts with expertise in treating patients with hypertension, including two internists, two cardiologists, and one nephrologist.”
> “Clinical experts emphasized that single pill combinations can help increase adherence to medications, but that some individuals with hypertension remain uncontrolled or have resistant hypertension even when they are taking medications regularly.”
> “For such individuals, mineralocorticoid receptor antagonists such as spironolactone are the preferred option; however, spironolactone may be difficult to take due to side effects, particularly for men.”
> “Finally, we heard that chronic kidney disease can complicate treatment for hypertension, as each of the three first-line therapies has limitations in this population”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.2-10"></a>

### Care setting: prescribers targeted by the manufacturer

> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”
> “It is about a 60/40 split, primary care/specialty, the bulk of the specialty being cardiologists.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

> “The trial was designed to evaluate lorundrostat in a uHTN or rHTN population at the highest risk, which would normally be treated by a specialist, given the severity of their condition.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

### Care setting: roles of the hypertension care team

| Team member | Role |
| --- | --- |
| “Primary care physician/cardiologist, physician assistant or associate/nurse practitioner/advanced practice nurse” | “Routine and complex hypertension care, managing primary care issues” |
| “Nephrologist, endocrinologist, hypertension specialist” | “Management of complex hypertension care, especially due to secondary causes, and/or resistant hypertension” |
| “Clinical Pharmacist” | “Comprehensive medication management, identification of medication-related interactions, and educating patients on their medication regimen” |

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
